Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget

On June 9, the House Appropriations Committee passed its version of the fiscal year 2027 spending bill for Labor, Health and Human Services, and Education.

June 12, 2026

Vol.52 No.23

By Paul Goldberg

As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded

Last week, Wafik El-Deiry, a cancer researcher at Brown University, showed up at a Senate hearing to talk about what he sees as dangers of the COVID-19 vaccine.

NCI selects UChicago Medicine as a lead site for clinical trials

The University of Chicago Medicine Comprehensive Cancer Center has been granted a six-year, $5 million grant from NCI.

June 12, 2026

Vol.52 No.23

Clinical Roundup

Tafasitamab + lenalidomide and R-CHOP improves PFS, phase III frontMIND trial finds

The phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, has produced positive results.

June 12, 2026

Vol.52 No.23

Clinical Roundup

Teclistamab improves outcomes in relapsed MM, phase III trial finds

An international phase III study showed that patients with relapsed multiple myeloma treated with teclistamab lived longer and remained in remission significantly longer than patients receiving standard therapies.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer, according to the results of a multicenter clinical trial led by researchers at the Johns Hopkins University School of Medicine, Johns Hopkins Kimmel Cancer Center, Department of Radiation Oncology and Molecular Radiation Sciences, and Brady Urological Institute.

June 05, 2026

Vol.52 No.22

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

YOU MAY BE INTERESTED IN

House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget

As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded

NCI selects UChicago Medicine as a lead site for clinical trials

Tafasitamab + lenalidomide and R-CHOP improves PFS, phase III frontMIND trial finds

Teclistamab improves outcomes in relapsed MM, phase III trial finds

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Renew today!

Subscriber content

Never miss an issue!

Login

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

YOU MAY BE INTERESTED IN

House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget

As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick labThe job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded

NCI selects UChicago Medicine as a lead site for clinical trials

Tafasitamab + lenalidomide and R-CHOP improves PFS, phase III frontMIND trial finds

Teclistamab improves outcomes in relapsed MM, phase III trial finds

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Never miss an issue!

Login

As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded